Neurobiological adds VP from Eisai
Executive Summary
Former Eisai international project team leader David Levy, MD, is joining Neurobiological Technologies as VP-clinical development. Levy will lead the clinical development effort for Viprinex (ancrod), a late-stage reperfusion therapy for acute ischemic stroke. NTI plans to initiate Phase III trials for Viprinex in the second half of 2005...